Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Net Margin (2020 - 2023)

Inhibikase Therapeutics (IKT) has disclosed Net Margin for 4 consecutive years, with 440356600.0% as the latest value for Q4 2023.

  • Quarterly Net Margin fell 44034978036.0% to 440356600.0% in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 2006393700.0% through Sep 2024, down 200638752188.0% year-over-year, with the annual reading at 7711.98% for FY2023, 697419.0% up from the prior year.
  • Net Margin for Q4 2023 was 440356600.0% at Inhibikase Therapeutics, down from 5993.38% in the prior quarter.
  • The five-year high for Net Margin was 187.4% in Q1 2021, with the low at 440356600.0% in Q4 2023.
  • Average Net Margin over 4 years is 27549285.01%, with a median of 5660.72% recorded in 2023.
  • The sharpest move saw Net Margin skyrocketed 25252290bps in 2022, then tumbled 2000000000bps in 2023.
  • Over 4 years, Net Margin stood at 708.85% in 2020, then plummeted by -36487bps to 259342.54% in 2021, then soared by 97bps to 6819.64% in 2022, then plummeted by -6457080bps to 440356600.0% in 2023.
  • According to Business Quant data, Net Margin over the past three periods came in at 440356600.0%, 5993.38%, and 5328.07% for Q4 2023, Q3 2023, and Q2 2023 respectively.